Literature DB >> 9831218

Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation.

M I Johnson1, M C Robinson, C Marsh, C N Robson, D E Neal, F C Hamdy.   

Abstract

BACKGROUND: Apoptosis-regulating genes have been shown to be important in the biology of prostate cancer. The aim of this study was to examine and correlate the expression of the apoptosis-regulating genes bcl-2, bax, and p53 with the frequency of apoptosis and rate of proliferation in benign prostatic epithelium (BP), prostate cancer, and high-grade prostatic intraepithelial neoplasia (HGPIN), which is currently considered the most likely precursor of prostate cancer.
METHODS: Forty-four patients with histologically proven prostate cancer were investigated. All the men underwent radical prostatectomy. Immunohistochemistry was performed to assess expression of bcl-2, bax, and p53, and proliferation rate, as measured by the Ki-67 index. The frequency of apoptotic bodies was assessed by morphological criteria.
RESULTS: The apoptotic index (AI) was highest in prostate cancer, and was significantly greater in HGPIN compared to benign prostate. The Ki-67 index was greatest in cancer, intermediate in HGPIN, and lowest in BP. The AI was increased in areas of BP in patients treated with neoadjuvant androgen ablation. No change in AI was seen in treated cases of HGPIN or cancer. Accumulation of p53 protein was infrequent in prostate cancer (2/43: 4.6%), and was absent in HGPIN. Bcl-2 overexpression was present in 2.3% of cancers (1/43) and in 34.9% of cases of HGPIN (15/43). Bax expression was seen in all cases of cancer and HGPIN. There was no correlation between bcl-2 expression and the apoptotic and Ki-67 indices in HGPIN.
CONCLUSIONS: p53 and bcl-2 expression is infrequent in clinically organ confined prostate cancer. Bcl-2 expression is significantly higher in HGPIN than in both the associated prostate cancer and BP. The AI and Ki-67 index appeared intermediate in the putative precursor lesion HGPIN compared to prostate cancer and BP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831218     DOI: 10.1002/(sici)1097-0045(19981201)37:4<223::aid-pros3>3.0.co;2-o

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  16 in total

Review 1.  "No Turning Bax" in the combined battle against prostate cancer:.

Authors:  Ramji R Rajendran; Gary D Kao
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

2.  Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS.

Authors:  Hai-bo Cheng; Yun Bo; Wei-xing Shen; Xian-guo Ren; Jia-ni Tan; Zhi-rong Jia; Chang-Liang Xu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-03-06       Impact factor: 3.000

Review 3.  Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance.

Authors:  R Montironi; R Mazzucchelli; F Algaba; A Lopez-Beltran
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

4.  Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy.

Authors:  Herbert Augustin; Peter G Hammerer; Markus Graefen; Jüri Palisaar; Fedor Daghofer; Hartwig Huland; Andreas Erbersdobler
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-26       Impact factor: 4.553

Review 5.  Immunopathological prognostic and predictive factors in prostate cancer.

Authors:  E Sivridis; S Touloupidis; A Giatromanolaki
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

6.  Immunohistochemical expression of caspase-1 and -9, uncleaved caspase-3 and -6, cleaved caspase-3 and -6 as well as Bcl-2 in benign epithelium and cancer of the prostate.

Authors:  Ramesh Ummanni; Ulrike Lehnigk; Uwe Zimmermann; Christian Woenckhaus; Reinhard Walther; Jürgen Giebel
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

7.  Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer.

Authors:  Vijayalakshmi Ananthanarayanan; Ryan J Deaton; Ximing J Yang; Michael R Pins; Peter H Gann
Journal:  BMC Cancer       Date:  2006-03-17       Impact factor: 4.430

8.  Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker.

Authors:  S J Chia; W Y Tang; J Elnatan; W M Yap; H S Goh; D R Smith
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

9.  Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.

Authors:  Takeharu Ogura; Yoshiyuki Tanaka; Hiroki Tamaki; Mamoru Harada
Journal:  Int J Oncol       Date:  2016-04-08       Impact factor: 5.650

10.  Prostate Tumor Overexpressed 1 (PTOV1) Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Poor Survival Outcomes.

Authors:  Qi Yang; Huanxin Lin; Shu Wu; Fangyong Lei; Xi Zhu; Libing Song; Minghuang Hong; Ling Guo
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.